Drew L Sellers
Overview
Explore the profile of Drew L Sellers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cardle I, Scherer D, Jensen M, Pun S, Sellers D
ACS Nano
. 2025 Jan;
19(5):5750-5768.
PMID: 39869930
The recent development of modular universal chimeric antigen receptor (CAR) T-cell platforms that use bifunctional adaptor intermediates to redirect engineered T-cell effector function has greatly expanded the capabilities of adoptive...
2.
Cardle I, Raman J, Nguyen D, Wang T, Wu A, Sellers D, et al.
ACS Appl Mater Interfaces
. 2025 Jan;
17(3):4543-4561.
PMID: 39788927
Selective therapeutic targeting of T-cell malignancies is difficult due to the shared lineage between healthy and malignant T cells. Current front-line chemotherapy for these cancers is largely nonspecific, resulting in...
3.
Nguyen D, Song K, Jokonya S, Yazdani O, Sellers D, Wang Y, et al.
ACS Cent Sci
. 2024 May;
10(5):1117.
PMID: 38799659
[This corrects the article DOI: 10.1021/acscentsci.3c01310.].
4.
Nguyen D, Song K, Jokonya S, Yazdani O, Sellers D, Wang Y, et al.
ACS Cent Sci
. 2024 Apr;
10(3):666-675.
PMID: 38559305
The Stimulator of Interferon Genes (STING) pathway is a promising target for cancer immunotherapy. Despite recent advances, therapies targeting the STING pathway are often limited by routes of administration, suboptimal...
5.
Nance E, Pun S, Saigal R, Sellers D
Nat Rev Mater
. 2024 Mar;
7(4):314-331.
PMID: 38464996
Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug development remains challenging, with high costs, long pathways to clinical use and high failure rates. The CNS...
6.
Underhill H, Karsy M, Davidson C, Hellwig S, Stevenson S, Goold E, et al.
Cancer Res
. 2024 Jan;
84(7):1149-1164.
PMID: 38270917
Significance: True2 is a next-generation sequencing workflow that facilitates unbiased discovery of somatic mutations across the full range of variant allele frequencies, which could help identify residual disease vulnerabilities for...
7.
Sellers D, Lee K, Murthy N, Pun S
J Control Release
. 2023 Jan;
354:188-195.
PMID: 36596342
Gene therapy approaches that utilize Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) ribonucleases have tremendous potential to treat human disease. However, CRISPR therapies delivered by integrating viral vectors are limited...
8.
Zhao Y, Fallas J, Saini S, Ueda G, Somasundaram L, Zhou Z, et al.
EMBO Rep
. 2021 Oct;
22(12):e53471.
PMID: 34698433
Angiopoietins 1 and 2 (Ang1 and Ang2) regulate angiogenesis through their similar F-domains by activating Tie2 receptors on endothelial cells. Despite the similarity in the underlying receptor-binding interaction, the two...
9.
Kacherovsky N, Yang L, Dang H, Cheng E, Cardle I, Walls A, et al.
Angew Chem Int Ed Engl
. 2021 Jul;
60(39):21211-21215.
PMID: 34328683
The coronavirus disease 2019 (COVID-19) pandemic has devastated families and disrupted healthcare, economies and societies across the globe. Molecular recognition agents that are specific for distinct viral proteins are critical...
10.
Cardle I, Jensen M, Pun S, Sellers D
J Biol Chem
. 2021 Apr;
296:100657.
PMID: 33857478
The integrin αvβ6 is an antigen expressed at low levels in healthy tissue but upregulated during tumorigenesis, which makes it a promising target for cancer imaging and therapy. A20FMDV2 is...